Kaitlyn Bader, Assistant Managing Editor

In this episode, Renata Block, DMSc, MMS, PA-C, welcomed Obehi Oriaifo, DNP, FNP-BC, DCNP, founder of DermaNP Solutions, to discuss expanding teledermatology access for rural and underserved patients.

Derm Dispatch host Renata Block, DMSc, MMS, PA-C, and Obehi Oriaifo, DNP, FNP-BC, DCNP, founder of DermaNP Solutions, discuss barriers driving demand for teledermatology in rural and underserved communities.

The FDA approval, based on phase 3 VALOR trial data, makes brepocitinib the first targeted therapy specifically indicated for dermatomyositis.

A secondary analysis of the phase 3 VALOR trial found brepocitinib 30 mg nearly doubled remission-level skin responses and improved itch as early as week 4 compared with placebo.

Heather Woolery-Lloyd, MD, discusses how new linear hair growth rate data translates into real-world results for patients.

Heather Woolery-Lloyd, MD, reviews a new clinical study quantifying linear hair growth rate across 4 Nutrafol formulations.

Review 10 evidence-based answers on GPP pathophysiology, diagnosis, and IL-36-targeted management, drawn from National Psoriasis Foundation consensus and emergency medicine literature.

Aaron Farberg, MD, outlines common triggers of generalized pustular psoriasis flares and the role of IL-36 targeted therapy.

Aaron Farberg, MD, reviews the diagnostic challenges of generalized pustular psoriasis and its common mimics across care settings.

Aaron Farberg, MD, discusses why generalized pustular psoriasis warrants its own awareness day and how it differs immunologically from plaque psoriasis.

Jerry Shapiro, MD, explains VDPHL01's cardiac safety profile and patient-reported outcomes in a phase 2 trial for female pattern hair loss.

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses TAMES-02 phase 2 trial enrollment and a new blister burden end point in EBS.

Leon Kircik, MD, discusses the allosteric binding mechanism and safety profile data of zasocitinib in hard-to-treat psoriasis presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Jerry Shapiro, MD, discusses rapid hair growth and safety findings for oral minoxidil, VDPHL01, in female pattern hair loss.

The accelerated FDA approval, based on Replimune's phase 2 IGNYTE trial data, gives clinicians a new second-line option for adults with advanced melanoma progressing after anti-PD-1 therapy.

Leon Kircik, MD, outlines phase 3 zasocitinib data on palmoplantar psoriasis skin clearance presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Karen McGuire, PhD, CEO and co-founder of BioMendics, explains what fast track status means for the investigational treatment and details the drug's mechanism of action in EBS.

Leon Kircik, MD, discusses zasocitinib scalp psoriasis clearance rates from the LATITUDE 1 and 2 trials presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Two phase 3 trials of Pfizer's ritlecitinib met co-primary end points for facial and total repigmentation in nonsegmental vitiligo at week 52, prompting plans for global regulatory filings.

RAD 2026 experts unpacked new IL-13, JAK, STAT6 and OX40 options, CHE and pediatric gaps, plus overlooked comorbidities shaping AD care.

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses why epidermolysis bullosa simplex remains a difficult gene therapy target.

In the latest episode of Don't Be Rash, host Andrew Krakowski, MD, is joined by Raegan D. Hunt, MD, PhD, to discuss newborn skin barrier development, umbilical cord care, and evidence-based product selection.

Linda Stein Gold, MD, presents tapinarof cream as a long-term, nonsteroidal option for pediatric atopic dermatitis based on data presented at the 2026 Society for Pediatric Dermatology Annual Meeting.

Linda Stein Gold, MD, discusses pooled phase 3 tapinarof cream data across pediatric atopic dermatitis age groups presented at the 2026 Society for Pediatric Dermatology meeting.

Sanofi will not submit the OX40-ligand antibody for regulatory review, citing efficacy and safety data insufficient to improve upon current standard-of-care treatments for moderate to severe AD.

In this episode, Renata Block, DMSCc, MMS, PA-C, discusses the new ICD-10 code for topical steroid withdrawal with Kelly Barta, the president and executive director of the International Topical Steroid Awareness Network.

Dermatologists and oncologists at a Dermatology Times Evolving Paradigms event in Boston compared immunotherapy selection, referral practices and surveillance strategies in advanced cutaneous squamous cell carcinoma.

Derm Dispatch host Renata Block, DMSCc, MMS, PA-C, and Kelly Barta, president and executive director of the International Topical Steroid Awareness Network, discuss the new ICD-10 code for topical steroid withdrawal and ITSAN's international patient registry.

New phase 3 data presented at the AAD Innovation Academy show zasocitinib achieved high rates of clear or almost clear skin at the scalp, palms, soles, and nails at week 16.

Clinicians at a Dermatology Times Case-Based Roundtable event worked through 3 vitiligo cases spanning new-onset, widespread, and pediatric disease, weighing treatment sequencing against real-world access barriers.